Topics

Human medicines European public assessment report (EPAR): Simponi, golimumab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Arthritis, Rheumatoid, Date of authorisation: 01/10/2009, Revision: 36, Status: Authorised

06:15 EDT 11 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Simponi, golimumab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Arthritis, Rheumatoid, Date of authorisation: 01/10/2009, Revision: 36, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Simponi, golimumab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Arthritis, Rheumatoid, Date of authorisation: 01/10/2009, Revision: 36, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Simponi, golimumab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Arthritis, Rheumatoid, Date of authorisation: 01/10/2009, Revision: 36, Status: Authorised"

Quick Search

Relevant Topics

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Arthritis
Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...